SITE003-0249

SITE003 (CAN) › SITE003-0249

SITE003-0249

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-06-23

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-03 (study day 39); relationship: not assessed

moderate assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 22); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.